Effect of iron sucrose on intradialytic blood pressure in patients receiving maintenance hemodialysis treatment
Open Access
- 20 February 2026
- journal article
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 7 (1) , 14-19
Abstract
Aims: There are studies showing that IV iron sucrose is vasoactive and causes changes in intradialytic blood pressure in hemodialysis patients. Intradialytic hypotension has been associated with vascular thrombosis, inadequate dialysis, and increased mortality. Intradialytic hypertension, has been shown in some studies to be associated with increased cardiovascular mortality and an increase in the frequency of hospitalization. In this study, we aimed to investigate the effect of iron sucrose on intradialytic blood pressure in hemodialysis patients.Methods: In this study, 59 patients undergoing hemodialysis three times a week had their blood pressure measured before hemodialysis and recorded at minute 0. 100 mg/5 ml iron sucrose was administered as an IV infusion during the first 30 minutes of dialysis treatment, and blood pressure was measured and recorded every 30 minutes. The same patient's blood pressure was measured every 30 minutes during the next hemodialysis session without iron sucrose treatment. Results: Intradialytic hypotension developed in two different patient; one patient in the session in which iron sucrose was given and one in the session in which iron sucrose was not given. There was no significant difference in intradialytic hypertension between the groups according to all three definitions of intradialytic hypertension (p=0.134; 0.523; and 1, respectively).Conclusion: We found that iron sucrose administration does not cause both intradialytic hypotension and intradialytic hypertension.Keywords
This publication has 28 references indexed in Scilit:
- Association of peridialytic, intradialytic, scheduled interdialytic and ambulatory BP recordings with cardiovascular events in hemodialysis patientsJournal Of Nephrology, 2022
- Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceKidney International, 2020
- Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies ConferenceKidney International, 2016
- Non-transferrin-bound iron is associated with biomarkers of oxidative stress, inflammation and endothelial dysfunction in type 2 diabetesJournal of Diabetes and its Complications, 2015
- The Safety of Intravenous Iron PreparationsMayo Clinic Proceedings, 2015
- NoticeKidney International Supplements, 2012
- Iron supplementation to treat anemia in patients with chronic kidney diseaseNature Reviews Nephrology, 2010
- Ferritin for the clinicianBlood Reviews, 2009
- Impact of biofeedback-induced cardiovascular stability on hemodialysis tolerance and efficiencyKidney International, 2000
- A randomized controlled study of iron supplementation in patients treated with erythropoietinKidney International, 1996